[Clinical studies of cefotaxime, administration in intravenous drip infusion, for infectious diseases in the field of obstetrics and gynecology (author's transl)].
Therapeutic efficacy and safety of a new cephalosporin for injection, cefotaxime (CTX) have been examined in gynecological infection cases. CTX has demonstrated in this study excellent therapeutic efficacy in infections with aerobes only, anaerobes only and with mixture of aerobes and anaerobes. No side effect has been observed in our patients who had been administered total dose of 8 approximately 28 g during the period of 4 approximately 7 days.
D000328:Adult; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002439:Cefotaxime / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000382:microbiology; D006801:Humans; D007263:Infusions, Parenteral; D008875:Middle Aged; D011247:Pregnancy; D011645:Puerperal Infection / Q000188:drug therapy
D002439:Cefotaxime